Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

(Reuters) -Advisers to the U.S. Food and Drug Administration on Tuesday recommended that the agency authorize Moderna Inc's COVID-19 vaccine for children and teens aged 6 to 17 years of age.

U.S. FDA advisers back Moderna COVID vaccine for 6-17 year olds

The authorization sets the stage for Wednesday's meeting, when the same advisors will consider vaccines from Pfizer and Moderna for younger children.

FDA Advisors Back Moderna Covid-19 Vaccine for 6- to 17-Year-Olds

NEW YORK — An FDA advisory panel on Tuesday endorsed Moderna's MRNA, +3.78% COVID-19 vaccine for teens and school-age children aged 6-17.

FDA panel supports Moderna's COVID-19 vaccine for kids aged 6-17

Advisers to the U.S. Food and Drug Administration on Tuesday recommended the authorization of Moderna Inc's COVID-19 vaccine for children and teens aged 6 to 17 years of age.

U.S. FDA advisers back authorization of Moderna COVID vaccine for ages 6-17

FDA advisors voted to recommend Moderna's vaccine for use in kindergarteners through high schoolers after an all-day meeting.

FDA committee recommends Moderna Covid vaccine for kids age 6 to 17

Moderna plans to invest around 500 million euros ($520.60 million) in a new laboratory in Spain to boost its production of vaccines, Spanish Prime Minister Pedro Sanchez said on Tuesday.

Moderna to invest 500 million euros in Spain, PM Sanchez says

Pfizer

Federal health officials said Sunday that Pfizer's COVID-19 vaccine appears safe and effective for children below the age of five, clearing another hurdle on the path toward adding that group to the nation's vaccine program.

FDA says Pfizer 3-shot vaccine safe for children under 5, ahead of panel meeting that will also review Moderna's 2-shot regimen

The FDA's assessment comes just days before an independent panel is set to meet and decide whether to recommend approving the vaccine for young children.

Pfizer, Moderna Vaccines Are Effective In Young Children, FDA Says—Here's How They Differ And What Happens Next

3 Reasons Why Moderna Stock Is so Cheap Right Now

The Street remains unconvinced with Moderna's ex-COVID vaccines pipeline, as it estimates peak revenue and profitability in FY22. We think it explains why the market has de-rated MRNA stock. However, our price action analysis suggests a formidable double-bottom bear trap could have formed. As a result, we believe it's increasingly likely that the worst is truly over.

Moderna: The Worst Is Likely Over

Moderna's (MRNA) bivalent COVID booster candidate targeting the Omicron variant achieved all pre-specified endpoints in a phase II/III study.

Moderna's (MRNA) Omicron-Specific Booster Jab Meets Study Goal

Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday as vaccine stocks fall in sympathy with Novavax Inc (NASDAQ: NVAX) following reports the FDA's decision on the company's COVID-19 vaccine could be delayed. According to a CNBC report, citing an agency.

Why Moderna Stock Is Moving Lower Today

Shares of Moderna have tumbled 40% this year while Ark's Genomic Revolution ETF has fallen nearly 50%.

Cathie Wood's Ark Invest Buys Moderna Stock After $100 Billion Crash—And Sells Rival Vaccine-Maker Pfizer

Moderna Inc has unveiled a new Omicron Covid-19 vaccine that it says is five times more effective at boosting antibodies compared to its previous jab. The vaccine, which would also protect against the first Wuhan strain, might only need to be administered once a year as a result.

New Moderna Covid-19 vaccine five times more effective

Moderna is following through on its promises.

Here's Why Moderna May Dominate the Vaccine Market This Fall

Moderna, Inc. (NASDAQ:MRNA ) 2022 Jefferies Global Healthcare Conference Call June 8, 2022 3:00 PM ET Company Participants Stephane Bancel - Chief Executive Officer Conference Call Participants Michael Yee - Jefferies Michael Yee Well, thank you everyone for joining us here at a great afternoon session here. I am up here with CEO of Moderna, Stephane Bancel.

Moderna, Inc. (MRNA) CEO Stephane Bancel Presents at 2022 Jefferies Global Healthcare Conference Call Transcript

Moderna said a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot.

Moderna says new version of COVID shot boosts Omicron protection

Moderna (MRNA) stock is in the spotlight today as investors react to news of a new vaccine for Covid-19 that works on Omicron. The post MRNA Stock Forecast: 3 Analysts Predict Where Moderna Will Go From Here appeared first on InvestorPlace.

MRNA Stock Forecast: 3 Analysts Predict Where Moderna Will Go From Here

Moderna's MRNA, +3.95% experimental next-generation COVID-19 vaccine provides more protection against omicron than the original shot, and the company is aiming to make it available to Americans this summer.

Moderna's next-generation COVID-19 shot provides ‘superior' protection against omicron

Moderna Inc (NASDAQ:MRNA) revealed earlier a study of an upgraded version of its Covid-19 vaccine, which also targets the Omicron strain, produced a better immune as a booster than its original shot, raising virus-neutralizing antibodies eightfold.

Moderna Stock Pops on Upgraded Covid-19 Booster Data

On Wednesday, June 8, Moderna (NASDAQ: MRNA) announced an enhanced version of their coronavirus vaccination designed to protect against the.

What's next for Moderna stock as firm announces modified booster against Corona strains

Moderna's modified Covid-19 booster shot that targets the Omicron variant shows a stronger immune response than the original vaccine.

Moderna Booster Targeting Omicron Shows Stronger Immune Response Than Original Vaccine

Shares of Moderna Inc. MRNA, +3.81% were up 2.1% in premarket trading on Wednesday after the company said its experimental bivalent COVID-19 vaccine that targets the original strain of the virus and the omicron variant produced a higher antibody response that its original COVID-19 booster shot one month after administration. The preliminary data from the Phase 2/3 study with 437 participants was shared in a news release.

Moderna says its bivalent COVID-19 shot produced a better response against omicron than its booster

Moderna chief executive Stéphane Bancel said early data suggests the bivalent shot could provide more long-lasting protection against variants of concern than the company's original formula alone.

Moderna's Booster Shot Targeting Omicron And Original Strain Could Be Available Late Summer After Promising Trials

Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant mRNA-1273.214 Exhibited an 8-Fold Boost in Neutralizing Geometric Mean Titers Against Omicron Among Baseline Seronegative Participants Safety and Tolerability Profile for mRNA-1273.214 is Consistent with Prior Booster Dose of mRNA-1273 Regulatory Submission Planned for Coming Weeks to Enable Use of mRNA-1273.214 For Fall Booster Conference Call to be Held Today At 8:00 AM ET CAMBRIDGE, MA / ACCESSWIRE / June 8, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern. A 50 µg booster dose of mRNA-1273.214 met all pre-specified endpoints including superior neutralizing antibody response (geometric mean ratio) against the Omicron variant one month after administration when compared to the original mRNA-1273 vaccine.The booster dose of mRNA-1273.214 was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 µg dose level.

News for Moderna Stock (MRNA)